Abstract 197P
Background
Tumor mutation burden, intratumor heterogeneity and the cancer related immune infiltrate are associated with response to target and immune therapies in several cancer types. The aim of this study is to establish a computational pathology (CPath) pipeline for investigating useful histopathological features in hematoxylin and eosin (H&E) whole slide images (WSIs). The pipeline allows for the segmentation and classification of nuclei. As an application, a machine learning approach is used to quantify intratumor heterogeneity (ITH) and tumor-infiltrating lymphocyte (TIL) scores.
Methods
We randomly selected 178 invasive ductal carcinomas WSIs from the TCGA database to process. Image annotation and nuclei detection were performed on QuPath by a pathologist using StarDist and used to train a SVM-based nuclei type classifier. The classifier was trained to distinguish between tumor, lymphocyte, and stroma. A total of 113.211 nuclei images were extracted using OpenSlide and used to train an autoencoder for dimensionality reduction. The variability of the WSIs was computed by applying a statistical measure of dispersion to the feature vectors. The TIL score was computed as the average minimum distance between a tumor cell and its nearest lymphocyte neighbor. We used the mutation burden, the ITH, PAM50 classification, nuclear and histological grades data from [https://doi.org/10.1038/nm.3984] to validate our ITH score. The percentage of infiltrating lymphocytes inferred by the quanTIseq pipeline based on RNAseq data was used to validate the SVM model.
Results
The nuclei classifier achieved 88% accuracy on the test set and the 96%/92% sensitivity to tumor/lymphocyte on a validation dataset. The mean squared error of the autoencoder was 0.0004 in the test set. The ITH score was associated with the clonal number of a tumor (x2 = 8.8, p= 0.03). Finally, we observed a positive correlation between the TIL/tumor ratio inferred by the CPath pipeline and the total number of T lymphocytes inferred by quanTIseq (Spearman= 0. 34, p < 0.0001).
Conclusions
We explored a CPath pipeline for detecting and classifying nuclei. The pipeline was used to compute ITH and TIL scores which correlated with validation data. Thus, validating our pipeline.
Legal entity responsible for the study
D.G. Tiezzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
60P - Adaptive NK cells as a therapeutic option for childhood leukaemia
Presenter: Zoya Eskandarian
Session: Poster Display
61P - Unlocking the Power of Natural Killer Cells: Precision Selection with Cutting-Edge Microfluidics
Presenter: Neelima KC
Session: Poster Display
63TiP - A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen: MIZAR trial
Presenter: Qing Xu
Session: Poster Display
68P - Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE
Presenter: Solange Peters
Session: Poster Display
70P - LIST (Lung Initiative on Sequence Therapy), a real-world study of nivolumab for advanced NSCLC in France: first effectiveness, safety, and IO-rechallenge results
Presenter: Benoît GODBERT
Session: Poster Display
72P - Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small-cell lung cancer?A multi-center, single-arm, phase 2 study
Presenter: Hui Zhouguang
Session: Poster Display
74P - A single-center, Phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Wen Feng Fang
Session: Poster Display
75P - Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation
Presenter: Ana Baramidze
Session: Poster Display